<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Menotropins: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Menotropins: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Menotropins: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12075" href="/d/html/12075.html" rel="external">see "Menotropins: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F192622"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Menopur</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912147"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Menopur</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F192658"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gonadotropin;</li>
<li>
                        Ovulation Stimulator</li></ul></div>
<div class="block doa drugH1Div" id="F192625"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a098e8e-cd3b-4d79-a881-46533554b6d2">Assisted reproductive technologies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Assisted reproductive technologies (females):</b>
<b>SUBQ:</b> Initial: 225 units once daily beginning on cycle day 2 or 3; Menotropins may be administered together with urofollitropin and the total initial dose of both products combined should not exceed 225 units (menotropins 150 units and urofollitropin 75 units; or menotropins 75 units and urofollitropin 150 units). Adjust dose after 5 days based on ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels. Do not make additional adjustments more frequently than once every 2 days or by &gt;150 units. Maximum daily dose: 450 units (of menotropins, or menotropins plus urofollitropin); treatment &gt;20 days is not recommended. Once follicular growth indicates an adequate ovarian response, administer hCG. Follow current clinical practice to reduce the risk of ovarian hyperstimulation syndrome.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fee773ef-3305-4831-a664-aaf734535931">Spermatogenesis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spermatogenesis (males) (off-label use): </b>
<b>IM:</b> Following pretreatment with hCG: 75 units 3 times per week with hCG twice weekly until sperm is detected in the ejaculate (4 to 6 months); if response is inadequate after 6 months, may increase menotropins dosage to 150 units 3 times per week for another 6 months (AACE [Petak 2002]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50989986"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987343"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F192600"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse effects and incidences may vary according to specific product, indication, dosage, or route of administration.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Genitourinary: Multiple gestation (35%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ovarian disease (3% to 8%), ovarian hyperstimulation syndrome (2% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5% to 7%), nausea (4% to 7%), abdominal cramps (3% to 7%), enlargement of abdomen (2% to 6%), gastrointestinal fullness (≥5%), vomiting (3%), diarrhea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginal hemorrhage (3% to 8%), pelvic pain (1% to 3%), breast tenderness (2%), ectopic pregnancy (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (2% to 8%), swelling at injection site (1% to 8%), pain at injection site (≤4%), inflammation at injection site (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Rash at injection site, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ovarian cyst, ovary enlargement</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemoperitoneum, ovarian neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Irritation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms, tachypnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fetal abnormality, ovarian torsion</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal distention, abdominal distress, acne vulgaris, acute respiratory distress syndrome, angioedema, atelectasis, cerebrovascular accident, embolism, facial edema, fatigue, hot flash, hypersensitivity reaction, laryngeal edema, local tissue necrosis, lower abdominal pain, malaise, occlusion of cerebral arteries, occlusive arterial disease (may result in loss of limb), pulmonary complications, pulmonary embolism, pulmonary infarct, thromboembolism, thrombophlebitis (includes venous), thrombosis</p></div>
<div class="block coi drugH1Div" id="F192612"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to menotropins or any component of the formulation; primary ovarian failure as indicated by a high follicle-stimulating hormone level; uncontrolled nongonadal endocrinopathies (eg, thyroid, adrenal, pituitary); pituitary or hypothalamic tumors; sex hormone-dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement not due to polycystic ovary syndrome; pregnancy.</p></div>
<div class="block war drugH1Div" id="F192597"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity and anaphylactic reactions have been reported; discontinue use for serious reactions and treat appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian enlargement: The lowest effective dose should be used to decrease the risk of abnormal ovarian enlargement. If ovaries are abnormally enlarged on the last day of menotropin treatment, follow current clinical practice to reduce the risk of ovarian hyperstimulation syndrome (OHSS).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian hyperstimulation syndrome: OHSS is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of hCG treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Mild/moderate OHSS signs/symptoms may include abdominal distention/discomfort, diarrhea, nausea, vomiting, and mild/moderate enlargement of ovaries/ovarian cysts. Severe OHSS signs/symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, hydrothorax, nausea/vomiting (intractable), pleural effusion, rapid weight gain, venous thrombosis, and large ovarian cysts. Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; Shmorgun 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian torsion: Has been reported following gonadotropin treatment; may be related to OHSS, prior ovarian torsion, prior or current ovarian cyst, polycystic ovaries, pregnancy, or prior abdominal surgery. Early diagnosis and prompt detorsion may limit the extent of ovarian damage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary effects: Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: In association with and separate from OHSS, thromboembolic events have been reported. Risk may be increased in patients with a personal or family history of thromboembolic events, severe obesity, or thrombophilia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: To minimize risks, use only at the lowest effective dose. Monitor ovarian response with transvaginal ultrasound; concurrent measurement of estradiol levels may also be useful.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple births: May result from the use of these medications; advise patients of the potential risk of multi-fetal gestation and multiple births before starting the treatment.</p></div>
<div class="block dosfc drugH1Div" id="F21024499"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">75 units of menotropins represents 75 units each of FSH activity and LH activity</p></div>
<div class="block foc drugH1Div" id="F192607"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution:</p>
<p style="text-indent:-2em;margin-left:4em;">Menopur: 75 units [supplied with diluent]</p></div>
<div class="block geq drugH1Div" id="F192593"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F192613"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Menopur Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 unit (per each): $280.09</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55901001"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution:</p>
<p style="text-indent:-2em;margin-left:4em;">Menopur: 75 units</p></div>
<div class="block adm drugH1Div" id="F192609"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">SubQ: Administer to alternating sites of the lower abdomen.</p></div>
<div class="block hazard drugH1Div" id="F49132780"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving and a gown are required during IM or subcutaneous administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F192608"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">For multiple follicle development and pregnancy in ovulatory women as part of an assisted reproductive technology cycle.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Prior to therapy, preform a complete gynecologic exam and endocrinologic evaluation to diagnose the cause of infertility; exclude the possibility of pregnancy; evaluate the fertility status of the male partner; exclude a diagnosis of primary ovarian failure.</p></div>
<div class="block off-label drugH1Div" id="F25575533"><span class="drugH1">Use: Off-Label: Adult</span><p>Stimulation of spermatogenesis</p></div>
<div class="block mst drugH1Div" id="F56381786"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299664"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6221521"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53914934"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Menotropins are used for the induction of ovulation and assisted reproductive technology (ART). Pregnancy should be excluded prior to treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Evaluate pregnancy status as well as the fertility of the male partner prior to ovulation induction.</p>
<p style="text-indent:0em;margin-top:2em;">Evaluate fertility status of the female partner prior to induction of spermatogenesis when treating males with hypogonadotropic hypogonadism (AACE [Petak 2002]).</p></div>
<div class="block pri drugH1Div" id="F192614"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Menotropins are used for the induction of ovulation and with assisted reproductive technology (ART); use is contraindicated in women who are already pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multifetal gestations/ births have been reported. The incidence of congenital abnormality may be slightly higher after ART than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, genetics, sperm characteristics).</p></div>
<div class="block brc drugH1Div" id="F20616170"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if menotropins is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F192605"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor follicular growth by transvaginal ultrasound to determine adequate ovarian response and timing of hCG administration. Concurrent measurement of estradiol levels may also be useful.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs and symptoms of ovarian hyperstimulation syndrome (OHSS) for at least 2 weeks following hCG administration. Initial symptoms of moderate to severe OHSS may include a sensation of bloating, abdominal pain, rapid weight gain, and decreased urine output (Shmorgun 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">OHSS: Monitoring of hospitalized patients should include albumin, degree of ascites, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, hydration, serum creatinine, urine output, urine specific gravity, signs of thromboembolism, vital signs, weight (daily or as necessary) and liver enzymes (weekly) (Shmorgun 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Males: Monitor for sufficient spermatogenesis (AACE [Petak 2002]).</p></div>
<div class="block pha drugH1Div" id="F192596"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Menotropins is a purified combination of follicle stimulating hormone (FSH) and luteinizing hormone (LH) extracted from the urine of postmenopausal women. Treatment provides ovarian follicular growth and maturation in females who do not have primary ovarian failure. Also stimulates spermatogenesis in males (off-label use)</p></div>
<div class="block phk drugH1Div" id="F192611"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Follicle-stimulating hormone (FSH) 11 to 13 hours (following multiple doses).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: FSH (following a single dose): 18 hours (SubQ).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F192615"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur | Pergonal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Menogon | Menopur | Meriofert</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Menopur</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Meriofert | Pergonal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Menogon | Menopur | Merional | Merional hg | Pergonal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Menogon | Menopur | Merional | Merional hg</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Humog | Menopur</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Pergonal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Le bao de | Menopur | Pergonal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Menopur | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Eigenorm | Humegon | Menogon | Menopur | Meriofert set | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menogon hp | Menopur | Menopur hp | Pergonal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Merapur | Pergonal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur | Merional</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Ivf-m | Menogon | Meriofert | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Menopur | Meriofert kit</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Gynogen | Humog | Menogon</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Menogon | Menopur | Meriofert | Pergonal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fertistartkit | Menogon | Menopur</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Meriofert | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Meriofert | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Menogon</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Menopur</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur | Meriofert kit | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur | Pergonal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Menogon | Menopur</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Pergonal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Folliglan mg hp | Fostine | Gmh | Gonotrop-f | Gynogen | Gynogen hp | Humegon | Humog | Ivf-m | Ivf-m hp | Lg ivf-m | Materna Hmg | Menodac | Menogon | Menolife | Menopur | Menovul | Nugon | Ovugraf | Pergonal | Puregraf | Reprogon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Meriofert</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Follitrin | Humegon | Menogon | Merional</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gonadoryl | Humegon | Pergonal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Gynogen hp | Humog | Humog hp | Menogon | Menopur | Merional</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Humenopin | Ivf-m | Ivf-m hp | Ivf-m hp multidose | Menogon | Menopur | Menopur multidose | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Ivf-m | Menogon | Menopur | Merional</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Merional | Merional hg | Pergonal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Meriofert | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Meriofert | Pergonal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Merapur | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Humog | Menopur | Pergonal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Meriofert</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Menopur</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Menopur</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Humog | Menopur</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Pergonal</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ferti m | Folinis | Ghm | Humegon | Ivf-m | Menogon | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Merional HP | Pergonal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Pergonal | Repronex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Menogon</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Menopur</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Menogon | Menopur | Merional</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur | Meriofert</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Gonadotropin | Humegon | Humog | Menogon | Menopausal gonadotropin | Menopur | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Merional | Merional HP | Pergonal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Menopur | Meriofert</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Menogon</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Menopur | Pergonal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Menopur | Meriofert | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Pergonal</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menogon | Pergonal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur | Merional</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Humog | Menogon | Menopur | Merional | Pergonal</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Humog | Menopur</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Menopur | Pergonal</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Pergonal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Humegon | Menopur | Merional hg | Pergonal</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Humog</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25574681">
<a name="25574681"></a>Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/menotropins-drug-information/abstract-text/25574681/pubmed" id="25574681" target="_blank">25574681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531097">
<a name="22531097"></a>Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/menotropins-drug-information/abstract-text/22531097/pubmed" id="22531097" target="_blank">22531097</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Menopur (menotropin) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals: April 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15260010">
<a name="15260010"></a>Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update [published correction appears in <i>Endocr Pract</i>. 2008;14(6):802-803]. <i>Endocr Pract</i>. 2002;8(6):440-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/menotropins-drug-information/abstract-text/15260010/pubmed" id="15260010" target="_blank">15260010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678032">
<a name="27678032"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/menotropins-drug-information/abstract-text/27678032/pubmed" id="27678032" target="_blank">27678032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29080733">
<a name="29080733"></a>Shmorgun D, Claman P. No-268-the diagnosis and management of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2017;39(11):e479-e486. doi: 10.1016/j.jogc.2017.09.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/menotropins-drug-information/abstract-text/29080733/pubmed" id="29080733" target="_blank">29080733</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9607 Version 167.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
